Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here. <\/p>\n
NanoViricides, Inc., (NYSE: NNVC) a pioneer in developing anti-viral nanomedicine drugs, is pleased to announce that its late-breaking abstract submission has been accepted for a poster presentation at the 36th Annual Meeting of the American Society of Virology (ASV). The ASV Meeting will be hosted and held at the University of Wisconsin-Madison, from June 24th to 28th, 2017 (https:\/\/extensionconferencecenters.uwex.edu\/asv2017\/<\/a>). <\/p>\n Dr. Brian Friedrich, Senior Virologist of the Company, will present the Company's work on the evaluation of nanoviricides drug candidates for effectiveness against the shingles virus (Varicella Zoster Virus, VZV, aka Human HerpesVirus-3 or HHV-3). He will present data on both safety and effectiveness of the nanoviricides drug candidates against VZV infection in multiple different cell lines. <\/p>\n NanoViricides has recently announced that two of the HerpeCide program drug candidates demonstrated complete (almost 100%) inhibition of the varicella-zoster virus (VZV, aka human herpesvirus 3 or HHV-3) at highest drug doses, whereas acyclovir at the same drug dose exhibited only about 70% inhibition of the virus. The nanoviricide drug candidates were almost five times as effective as acyclovir in these assays. No cytotoxicity was observed at any of the doses tested for the herpecide drug candidates. Details of these studies will be presented in the poster at the 2017 Annual Meeting of the ASV. <\/p>\n The NanoViricides poster, entitled \"Novel Nanoviricides Highly Effective against Varicella Zoster Virus in Cell Culture\" will be presented in Poster Session II, open for viewing from 4pm to 6pm on Monday, June 26th, 2017. <\/p>\n About NanoViricides: NanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. <\/p>\n <\/p>\n Read the original: Get instant alerts when news breaks on your stocks. Continue reading
\nNanoViricides (NNVC) Abstract Accepted for Poster Presentation at ASV - StreetInsider.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"